Ernexa Therapeutics Inc. Proceeds from Stock Options Exercised
Ernexa Therapeutics Inc. (ERNA) reported Proceeds from Stock Options Exercised of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2023-03-20
- Ernexa Therapeutics Inc. proceeds from stock options exercised for the quarter ending 2022-12-31 was $0.00.
- Ernexa Therapeutics Inc. proceeds from stock options exercised for the quarter ending 2022-09-30 was $0.00.
- Ernexa Therapeutics Inc. proceeds from stock options exercised for the quarter ending 2021-12-31 was $0.00.
- Ernexa Therapeutics Inc. proceeds from stock options exercised for the quarter ending 2021-09-30 was $0.00.
- Ernexa Therapeutics Inc. proceeds from stock options exercised for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Ernexa Therapeutics Inc. proceeds from stock options exercised for fiscal 2021 was $10.00K.
- Ernexa Therapeutics Inc. proceeds from stock options exercised for fiscal 2020 was $0.00.
- Ernexa Therapeutics Inc. proceeds from stock options exercised for fiscal 2014 was $44.00K, a 4300.00% increase from fiscal 2013.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 6 month as first filed | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 9 month as first filed | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 10-K · filed 2023-03-20 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $10.00K 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $10.00K 10-Q · filed 2022-11-14 | $10.20K 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $10.00K 10-Q · filed 2022-08-11 | $10.20K 10-Q · filed 2021-08-13 | ||||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01 | $0.00 derived: sum of 2 quarters · filed 2022-07-01 | $0.00 10-K/A · filed 2022-07-01 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-13 | |||||
| 2015-09-30 | $1.00K 10-Q · filed 2015-11-09 | $2.00K derived: sum of 2 quarters · filed 2015-11-09 | $1.00K 10-Q · filed 2016-11-09 | $2.00K derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2015-06-30 | $1.00K 10-Q · filed 2015-08-10 | $1.00K 10-Q · filed 2016-08-04 | $1.00K derived: sum of 3 quarters · filed 2016-03-15 | $23.00K derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | $0.00 derived: sum of 2 quarters · filed 2016-03-15 | $22.00K derived: sum of 3 quarters · filed 2016-03-15 | $39.00K derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $22.00K derived: sum of 2 quarters · filed 2016-03-15 | $39.00K derived: sum of 3 quarters · filed 2016-03-15 | $44.00K 10-K · filed 2016-03-15 | ||
| 2014-09-30 | $22.00K 10-Q · filed 2015-11-09 | $39.00K derived: sum of 2 quarters · filed 2015-11-09 | $44.00K 10-Q · filed 2015-11-09 | |||
| 2014-06-30 | $17.00K 10-Q · filed 2015-08-10 | $23.00K 10-Q · filed 2015-08-10 | ||||
| 2014-03-31 | $6.00K 10-Q · filed 2015-05-08 | |||||
| 2013-12-31 | $1.00K 10-K · filed 2015-03-27 | |||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | ||||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-15 | |||||
| 2012-12-31 | $0.00 10-K · filed 2014-03-31 | |||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $2.00K derived: sum of 2 quarters · filed 2013-03-29 | $2.00K derived: sum of 3 quarters · filed 2013-03-29 | $36.00K 10-K · filed 2013-03-29 | ||
| 2011-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $2.00K derived: sum of 2 quarters · filed 2012-11-09 | $36.00K 10-Q · filed 2012-11-09 | $36.00K derived: sum of 4 quarters · filed 2012-11-09 | ||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $34.00K 10-Q · filed 2012-08-14 | $34.00K derived: sum of 3 quarters · filed 2012-08-14 | $39.00K derived: sum of 4 quarters · filed 2012-08-14 | ||
| 2011-03-31 | $34.00K 10-Q · filed 2012-05-11 | $34.00K derived: sum of 2 quarters · filed 2012-05-11 | $39.00K derived: sum of 3 quarters · filed 2012-05-11 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $5.00K derived: sum of 2 quarters · filed 2012-03-30 | $61.00K 10-K · filed 2012-03-30 | |||
| 2010-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $61.00K 10-Q · filed 2011-11-14 | ||||
| 2010-06-30 | $56.00K 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |